XOMA Corporation (XOMA) Getting Somewhat Positive News Coverage, Accern Reports
Media stories about XOMA Corporation (NASDAQ:XOMA) have trended somewhat positive on Monday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. XOMA Corporation earned a news impact score of 0.20 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.5045328904886 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s analysis:
- XOMA Corporation (XOMA) Raised to Hold at Zacks Investment Research (americanbankingnews.com)
- XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference (feeds.benzinga.com)
- XOMA Corporation (XOMA) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)
XOMA Corporation (XOMA) traded up 0.61% on Monday, hitting $19.69. 94,564 shares of the company traded hands. The stock’s 50-day moving average is $11.46 and its 200 day moving average is $7.86. The stock’s market cap is $149.60 million. XOMA Corporation has a 12 month low of $3.96 and a 12 month high of $22.69.
Several research firms recently weighed in on XOMA. Zacks Investment Research downgraded shares of XOMA Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Wedbush restated a “hold” rating on shares of XOMA Corporation in a research report on Monday, August 14th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of XOMA Corporation in a research report on Thursday, August 10th. Finally, ValuEngine upgraded shares of XOMA Corporation from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $14.00.
COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/25/xoma-corporation-xoma-getting-somewhat-positive-news-coverage-accern-reports.html.
XOMA Corporation Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.